Dubai Health, the first integrated academic health system in Dubai, is embracing virtual reality (VR) technology to improve patient care across its hospitals and healthcare centers. This initiative kicks off with a study and implementation program at the Thalassemia Center, exploring the use of VR technology to reduce anxiety and pain during cannulation (needle insertion) procedures for thalassemia patients. This study, the first of its kind for this specific patient group in Dubai, holds promise for a more comfortable and positive healthcare experience.

Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), which leads the Learning and Discovery missions of Dubai Health, will conduct and document the study. Unlike prior studies that primarily relied on subjective experiences, this novel approach will incorporate objective measurements such as eye movement tracking and heart rate to assess the effectiveness of VR technology, marking a significant advancement in medical discovery.

Dr. Fatheya Abbas Al Khaja, Director of the Thalassemia Center, expressed her profound optimism for the initiative, stating, “The application of VR technology at the Thalassemia Center has the potential to transform the experience for patients undergoing cannulation procedures. Throughout my years at the Thalassemia Center, we have explored numerous modalities to alleviate the pain of our patients. This program epitomizes our Patient First promise to provide a more comfortable and anxiety-free experience, not just for the patients, but also for their families who witness this process. We are eagerly anticipating the results of this study.”

Separate from the MBRU study, the selected VR technology had been tested extensively. It demonstrated clinically effective results in 14 published and 30 ongoing studies, providing a solid foundation for its use in improving patient experiences.

This program marks the first phase of integrating VR technology across Dubai Health hospitals and healthcare centers, with plans to extend its application into medical procedures at Al Jalila Children's Hospital and Latifa Hospital. Beyond immediate application at the Thalassemia Center, the program also focuses on developing novel VR environments and experiences tailored to the local needs of patients in Dubai. The long-term vision is to develop future iterations of AI-powered VR technology to further personalize the patient experience, a collaborative effort engaging both MBRU students and our clinical staff.

“This program is the first of many to showcase how digital solutions can improve patient care within Dubai Health,” remarked Dr. Yacine Hadijat, Associate Professor of Innovation in Health Science and Digital Health at MBRU’s College of Medicine. “One of the inherent advantages of our integrated academic health system is the ability to cultivate a continuous cycle of improvement within our care, learning and discovery missions. By exploring digital innovations, such as VR technology, we are simultaneously training future healthcare professionals to champion patient-centered care and contribute toward the medical discovery of tech-enabled healthcare solutions. This multifaceted approach holds immense promise to transform the patient journey for countless individuals.”

By spearheading such initiatives, Dubai Health remains at the forefront of healthcare innovation, reaffirming its commitment to delivering patient-centered care and advancing the standard of medical excellence in the region.

Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), which leads the Learning and Discovery missions of Dubai Health, the first integrated academic health system in Dubai, joined forces with the United States Centers for Disease Control and Prevention (CDC) and National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH) to host the joint conference: Research and Public Health Priorities in the MENA Region: Lessons from the COVID-19 Pandemic and Future Preparedness.

Held at MBRU, the event brought together regional experts and stakeholders from the Middle East and North Africa (MENA), alongside counterparts from the U.S. and other regions to exchange insights and foster collaboration in addressing pressing public health challenges.

The U.S. CDC established the MENA Regional Office in Muscat, Oman in 2020 to strengthen public health collaborations in the region and enhance global health security. In addition to the CDC personnel in Muscat, CDC will soon place a Regional Technical Advisor for Emerging Infections and Zoonotic Diseases in Abu Dhabi to support additional efforts in UAE and the region. This presence, along with the NIAID in the region, fosters scientific and public health collaborations with the U.S., and the MENA region, including sharing best practices and innovations, such as this conference.

The conference welcomed approximately 200 delegates, including academics, healthcare practitioners, and public health professionals from 16 countries, including an impressive lineup of nearly 40 speakers and chairs and 40 abstract presenters. Featuring sessions, panel discussions, and abstract presentations, conference topics ranged from reflections on the COVID-19 pandemic's impact and predictions for future outbreaks, to strategies for preparedness and response. The conference also afforded opportunities for networking and collaboration among the participants.

The conference also featured keynotes by notable figures, including Deputy Chief of Mission Eric Gaudiosi, of the U.S. Mission to the UAE; H.E. Dr. Amer Sharif, Chief Executive Officer of Dubai Health, and President of MBRU; H.E. Professor Alawi Alsheikh-Ali, Deputy CEO of MBRU; from the U.S. Centers for Disease Control and Prevention (CDC), Dr. Henry Walke, Director of the Office of Readiness and Response, Dr. Kayla Laserson, Director for the Global Health Center, Heather Burke, Regional Director, U.S. CDC Middle East/North Africa Regional Office in Muscat, Oman, ; and from NIAID, Dr. Daniel Douek, Senior Investigator and Chief of the Human Immunology Section at the Vaccine Research Center, and Dr. Mohamed H. Sayegh, Senior Scientific Advisor to the Director.

In his opening keynote address, H.E. Dr. Amer Sharif, Chief Executive Officer of Dubai Health and President of MBRU, highlighted Dubai's proactive response to the COVID-19 pandemic, drawing upon his role as Chair of the Dubai COVID-19 Command and Control Center. He emphasized the significance of collaboration and working together in a coordinated approach toward advancing healthcare solutions.

He said, “We are proud to host healthcare leaders from all around the region and the U.S. for the Research and Public Health Priorities in the MENA Region conference here in Dubai. A new frontier of opportunities has been created since the COVID-19 pandemic, and now, more than ever, we stand at the cusp of a transformative era, where not only do we reflect upon lessons learned but also to chart new territories in a conducive environment that nurtures collaboration across the entire region and beyond. As Dubai’s first integrated academic health system, we believe that through uniting efforts, we advance health and shape a brighter future for all.”

In his opening remarks, DCM Gaudiosi stated, “Supported by the U.S. COVID-19 response supplemental funding and facilitated by the support of the U.A.E government and the U.S. diplomatic missions in the region, our gathering today focuses on health security, preparedness, and response—a testament to our shared priorities and our collective will to invest in healthier futures.”

Indeed, many of the participants were on the front lines during the COVID-19 pandemic – from clinicians, incident managers, and leaders in local, national, and global response. It was evident the importance of partnership, sharing of accurate information, forecasting and analytics to inform decision making, and health communications in protecting health not just in emergencies, but also in mass migration events and outbreak response. The conference concluded with energized participants with new and strengthened relationships and ideas for collaboration to predict, prepare, and be ready to respond to the next health threat.

Dubai Health, the first integrated academic health system in Dubai, has partnered with the Angelman Syndrome Foundation to establish the GCC’s first dedicated clinic at Al Jalila Children’s Hospital. This is the first-of-its-kind clinic in the region and aims to improve care for patients with Angelman Syndrome and raise awareness of this rare neurological disorder. The clinic will provide a supportive community hub where patients, families and caregivers can connect with experts and receive the best evidence-based care, bridging a gap in healthcare for those living with this condition.  

In line with Dubai Health’s Patient First promise, the partnership with the Angelman Syndrome Foundation represents new hope for individuals and families living with this rare neuro-genetic disorder. Affecting approximately one in 500,000 people worldwide, the early symptoms of Angelman Syndrome include a significant delay in obtaining developmental milestones such as walking within the first 12 months. Other clinical findings include speech delay, movement or balance disorder and often present with an apparent happy demeanor with frequent laughter and excitability.

The clinic will provide families in the UAE access to specialist healthcare professionals and evidence-based care while also enhancing future treatment through the power of Dubai Health’s integrated academic health system. Through harnessing the education and research that takes place within Dubai Health, this partnership aims to significantly improve the lives of patients and their families.

Dr. Abdulla Al Khayat, CEO of Al Jalila Children’s Hospital, said: “We are delighted to partner with The Angelman Syndrome Foundation to bring this specialized clinic to Al Jalila Children’s Hospital, part of Dubai Health care network. This crucial partnership is a beacon of hope for patients and families affected by this rare condition. By ensuring that we deliver the highest standard of care and driven by our Patient First promise, we hope to empower Angelman Syndrome patients and their families to lead fulfilling lives.”

Also commenting on the partnership, Amanda Moore, CEO of the Angelman Syndrome Foundation, said: "We are deeply honored to join forces with Dubai Health and Al Jalila Children's Hospital in this transformative initiative. This clinic will offer families in the UAE access to professionals with deep knowledge of Angelman Syndrome, expertise that has traditionally been challenging to locate. Raising awareness of rare conditions like Angelman Syndrome is crucial for early diagnosis and better patient outcomes. This initiative is part of our LADDER Learning Network, designed to bridge critical gaps in the healthcare landscape for families dealing with this rare disorder. We look forward to working closely with the team at Dubai Health to making a significant difference to the lives of patients and their families.”